Unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI)

Active Ingredient: Enoxaparin

Indication for Enoxaparin

Population group: only adults (18 - 65 years old)
Therapeutic intent: Curative procedure

Acute coronary syndrome:

Treatment of unstable angina and Non ST-segment elevation myocardial infarction (NSTEMI), in combination with oral acetylsalicylic acid.

For this indication, competent medicine agencies globally authorize below treatments:

100 IU/kg (1 mg/kg) in combination with antiplatelet therapy every 12 hours for 2-8 days

For:

Dosage regimens

Regimen A

Subcutaneous, 100 international units enoxaparin per kilogram of body weight, once every 12 hours, over the duration of 2 to 8 days.

Regimen B

Subcutaneous, 1 milligrams enoxaparin per kilogram of body weight, once every 12 hours, over the duration of 2 to 8 days.

Detailed description

For treatment of unstable angina and NSTEMI, the recommended dose of enoxaparin sodium is 100 IU/kg (1 mg/kg) every 12 hours by SC injection administered in combination with antiplatelet therapy. Treatment should be maintained for a minimum of 2 days and continued until clinical stabilization. The usual duration of treatment is 2 to 8 days.

Acetylsalicylic acid is recommended for all patients without contraindications at an initial oral loading dose of 150–300 mg (in acetylsalicylic acid-naive patients) and a maintenance dose of 75–325 mg/day long-term regardless of treatment strategy.

Dosage considerations

Injection should be made preferably when the patient is lying down. Enoxaparin sodium is administered by deep SC injection.

The administration should be alternated between the left and right anterolateral or posterolateral abdominal wall.

The whole length of the needle should be introduced vertically into a skin fold gently held between the thumb and index finger. The skin fold should not be released until the injection is complete. After administration, the injection site should not be rubbed.

Active ingredient

Enoxaparin

Enoxaparin is a LMWH with a mean molecular weight of approximately 4,500 daltons, in which the antithrombotic and anticoagulant activities of standard heparin have been dissociated. The active substance is the sodium salt.

Read more about Enoxaparin

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.